ストックスクリーナーアプリを入手
74.19
2.85%
-2.18
Nektar Therapeutics (NKTR) 最新ニュース
How Investors Are Reacting To Nektar Therapeutics (NKTR) Q2 Loss, ESOP Shelf Registration And Financing Flexibility - simplywall.st
JPMorgan Chase & Co. Initiates Coverage on Nektar Therapeutics (NASDAQ:NKTR) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Shareholders to Connect - ACCESS Newswire
Nektar Therapeutics chief R&D officer Zalevsky sells $13,388 in shares - Investing.com
Nektar Therapeutics CEO Howard W. Robin sells $30,087 in stock By Investing.com - Investing.com South Africa
Nektar Therapeutics CEO Howard W. Robin sells $30,087 in stock - Investing.com
Nektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 186 Shares of Stock - MarketBeat
Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells $30,087.64 in Stock - MarketBeat
Nektar (NKTR) Q2 2026 Earnings Call Transcript - AOL.com
Nektar Therapeutics Stock Historical Valuations | XTER:ITH0 - GuruFocus
Nektar Therapeutics (NKTR) exec sells shares only to cover taxes - Stock Titan
Nektar Therapeutics Stock Operating Data - GuruFocus
NKTR Stock Quote Price and Forecast - CNN
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
Nektar Therapeutics (XTER:ITH0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Nektar Therapeutics (XTER:ITH0) Stock News, Headlines & Updates - GuruFocus
Nektar Therapeutics (XTER:ITH0) Stock Price, Trades & News - GuruFocus
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets - Moomoo
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Shareholders to Reach Out - ACCESS Newswire
Nektar (NASDAQ: NKTR) exec to sell 186 shares, partly for taxes - Stock Titan
Nektar Therapeutics (NASDAQ: NKTR) insider plans 418-share sale - Stock Titan
NKTR Stock Skyrockets: Wall Street Sees Up To 200% Upside As Skin Trial Crushes Even Bull-Case Forecasts - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
2026-08-16 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation | NDAQ:NKTR | Press Release - Stockhouse
Nektar Therapeutics (NKTR) Stock Slides As Cash Burn Clouds Pipeline Progress - simplywall.st
Piper Sandler Reaffirms Their Buy Rating on Nektar Therapeutics (NKTR) - The Globe and Mail
NKTR SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Nektar Therapeutics (NKTR) Could Be 52% Undervalued After Q2 Earnings Surprise - Yahoo Finance
Two Seas Capital group (NKTR) reports 9.1% Nektar Therapeutics ownership via investment funds - Stock Titan
Biotechnology Value Fund group (NKTR) discloses 7.1% beneficial stake in Nektar - Stock Titan
Is Nektar Therapeutics (NKTR) Still Below Fair Value After Its Recent Run Up? - Sahm
Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming (NKTR) - Seeking Alpha
Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch - Yahoo Finance
Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus - TradingView
Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $192 - Moomoo
Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)? - simplywall.st
Boost Run, Nektar Therapeutics, Swarmer - TradingView
Nektar Therapeutics Q2 2026 Earnings Call Summary - Yahoo Finance
Nektar Therapeutics Boosts Cash to Over $1 Billion After Major Dilutive Equity Raises - Minichart
Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $151 - Moomoo
NEKTAR THERAPEUTICS Q2 2026: Revenue $10.1M, EPS $(1.23) — 10-Q Summary - TradingView
Nektar Therapeutics (NKTR) adds $1.02B cash while posting $85.5M loss - Stock Titan
Nektar Therapeutics (NKTR) (Q2 2026) Earnings Call Highlights: Respeg Phase 3 Momentum and ... By GuruFocus - Investing.com Canada
Nektar Therapeutics Cash Reaches $1.02 Billion After $373.8 Million Offering - Minichart
Nektar Therapeutics rated Strong Buy on REZPEG's promising Phase 3 trials for atopic dermatitis and alopecia areata. - Pluang
Nektar Raises Cash to Fund Rezpegaldesleukin Phase 3 Trials Through 2028 - The Clinical Trial Vanguard
Nektar Therapeutics (NKTR) (Q2 2026) Earnings Call Highlights: R - GuruFocus
Nektar Therapeutics Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Nektar beats Q2 2026 EPS but stock slips after hours - Investing.com Nigeria
Full Transcript: Nektar Therapeutics Q2 2026 Earnings Call - Benzinga
Nektar Therapeutics (NASDAQ:NKTR) Announces Earnings Results, Beats Expectations By $0.74 EPS - MarketBeat
Nektar Therapeutics reports results for the quarter ended June 30Earnings Summary - TradingView
Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Is Nektar Therapeutics (NKTR) Oversold After Q2 Earnings Miss? G - GuruFocus
Nektar Therapeutics posts Q2 2026 net loss $40.6M; cash and investments $1.023B - TradingView
Nektar Therapeutics Q2 Loss Narrows, Revenue Declines - marketscreener.com
Nektar: Q2 Earnings Snapshot - kare11.com
NEKTAR THERAPEUTICS ($NKTR) Releases Q2 2026 Earnings - Quiver Quantitative
Nektar Therapeutics Q2 revenue falls, net loss narrows - TradingView
Earnings Flash (NKTR) Nektar Therapeutics Posts Q2 Loss $1.23 Per Share, vs. FactSet Est of $1.97 Loss - marketscreener.com
Nektar Therapeutics Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):